In this study, we determined the impact of biomarkers of both Aβ and tau pathology quantified in the CSF on longitudinal changes of GMV in two independent large cohorts of CU individuals derived from the ALzheimer's and FAmilies (ALFA) and the European Prevention of Alzheimer's Disease (EPAD) studies. This evidence concerns the gene MAPT and Alzheimer disease.